MYD88
MYD88 (Myeloid differentiation primary response protein MyD88) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.
Overview
Adapter protein involved in the Toll-like receptor and IL-1 receptor signalling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription.
CIViC holds 5 clinical evidence items and 0 assertions across 2 variants, naming Paclitaxel, Ibrutinib, IRAK-1/4 Inhibitor and IMG-2005-5. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.00, somatic mutation 0.95). IntOGen calls it a driver in 10 cohorts (10 activating, 0 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MYD88 (Myeloid differentiation primary response protein MyD88) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.
- 1 · What it is
MYD88 (Myeloid differentiation primary response protein MyD88) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.
- 2 · What goes wrong in cancer
Adapter protein involved in the Toll-like receptor and IL-1 receptor signalling pathway in the innate immune response.
- 3 · How drugs use it
No product in this corpus aims at MYD88 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:7562 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q99836 (protein name, function text, keywords and locations (REST API)); CIViC gene MYD88 (5 evidence items, 0 assertions, 2 variants; diseases: Lymphoplasmacytic Lymphoma, Breast Cancer, Diffuse Large B-cell Lymphoma, Chronic Lymphocytic Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000172936 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.70, diffuse large B-cell lymphoma 0.72, B-cell chronic lymphocytic leukaemia 0.70, non-Hodgkin lymphoma 0.83, Waldenstrom macroglobulinemia 0.50, breast cancer 0.54 (GraphQL API, CC0)); IntOGen MYD88 (driver in 10 cohorts (Act 10, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Adapter protein involved in the Toll-like receptor and IL-1 receptor signalling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. Involved in IL-18-mediated signalling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. Upon TLR8 activation by GU-rich single-stranded RNA (GU-rich RNA) derived from viruses such as SARS-CoV-2, SARS-CoV and HIV-1, induces IL1B release through NLRP3 inflammasome activation. Location: Cytoplasm; Nucleus (UniProt). Locus 3p22.2 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.83 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Leukaemia: Open Targets association 0.74 with leukaemia (MONDO_0005059)
- Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254); CIViC evidence names this disease
- Diffuse large B-cell lymphoma: Open Targets association 0.72 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
- Acute lymphoblastic leukaemia: Open Targets association 0.70 with acute lymphoblastic leukaemia (MONDO_0004967)
- Chronic lymphocytic leukaemia: Open Targets association 0.70 with B-cell chronic lymphocytic leukaemia (MONDO_0004948); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; IntOGen calls it an activating (Act) driver in 10 cohorts; CIViC holds 5 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Lymphoplasmacytic Lymphoma.
Latest papers
topQuery for this target: (TITLE:"MYD88" OR ABSTRACT:"MYD88" OR TITLE:"MYD88 innate immune signal transduction adaptor" OR ABSTRACT:"MYD88 innate immune signal transduction adaptor" OR TITLE:"Myeloid differentiation primary response protein MyD88" OR ABSTRACT:"Myeloid differentiation primary response protein MyD88") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MYD88, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCCND3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetPAX5
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetTBL1XR1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetGATA3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetNT5C2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetBIRC3
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetCTCF
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetBCL10
Shares B-cell receptor / BTK signalling (to NF-κB), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.